Skip to main content

Table 1 Baseline characteristics by diagnosis period

From: Impact of the COVID-19 pandemic on diagnosis, stage, and initial treatment of breast cancer in the Netherlands: a population-based study

 

Weeks 2–8

Weeks 9–11

Weeks 12–13

Weeks 14–17

2018/2019a

2020

p

2018/2019a

2020

p

2018/2019a

2020

p

2018/2019a

2020

p

Patients

2547.5

2692

 

1074.5

995

 

737.5

436

 

1402

646

 

Age

            

 < 40

129.5 (5.1)

142 (5.3)

0.02

51 (4.8)

44 (4.4)

0.55

36.5 (5.0)

19 (4.4)

0.42

54 (3.9)

64 (9.9)

< 0.01

 40–49

389.5 (15.3)

372 (13.8)

158.5 (14.8)

128 (12.9)

104.5 (14.2)

62 (14.2)

204.5 (14.6)

111 (17.2)

 50–64

912.5 (35.8)

898 (33.4)

387.5 (36.1)

368 (37.0)

266.5 (36.1)

175 (40.1)

524.5 (37.4)

200 (31.0)

 65–74

674 (26.5)

771 (28.6)

284.5 (26.5)

282 (28.3)

206.5 (28.0)

121 (27.8)

358 (25.5)

118 (18.3)

 > 74

442 (17.4)

509 (18.9)

193 (18.0)

173 (17.4)

123.5 (16.8)

59 (13.5)

261 (18.6)

153 (23.7)

SES

            

 High

782.5 (30.7)

788 (29.3)

< 0.01

295.5 (27.5)

316 (31.8)

0.04

211.5 (28.7)

133 (30.5)

0.47

410.5 (29.3)

206 (31.9)

0.28

 Medium

992.5 (39.0)

1169 (43.4)

421 (39.2)

379 (38.1)

282.5 (38.3)

153 (35.1)

569.5 (40.6)

242 (37.5)

 Low

763.5 (30.0)

719 (26.7)

355 (33.0)

298 (30.0)

239.5 (32.5)

148 (33.9)

413.5 (29.5)

193 (29.9)

 Unknown

9 (0.4)

16 (0.6)

3 (0.3)

2 (0.2)

4 (0.5)

2 (0.5)

8.5 (0.6)

5 (0.8)

Morphology

            

 DCIS

309 (12.1)

352 (13.1)

0.44

119.5 (11.1)

125 (12.6)

0.33

79.5 (10.8)

65 (14.9)

0.03

178 (12.7)

42 (6.5)

0.00

 Invasive ductal

1761.5 ( 69.2)

1828 (67.9)

756 (70.4)

671 (67.4)

504.5 (68.4)

294 (67.4)

951 (67.8)

480 (74.3)

 Invasive lobular

342.5 (13.4)

380 (14.1)

135 (12.6)

141 (14.2)

122 (16.5)

55 (12.6)

198 (14.1)

92 (14.2)

 Other

134.5 (5.3)

132 (4.9)

64 (6.0)

58 (5.8)

31.5 (4.3)

22 (5.1)

75 (5.4)

32 (5.0)

Stage

            

 DCIS

309 (12.2)

352 (13.2)

0.25

119.5 (11.1)

125 (12.6)

0.69

79.5 (10.8)

65 (15.0)

0.09

178 (12.7)

42 (6.6)

< 0.01

 Stage I

1044.5 (41.1)

1075 (40.4)

446 (41.6)

418 (42.2)

306 (41.6)

167 (38.6)

559.5 (40.0)

212 (33.1)

 Stage II

828.5 (32.6)

891 (33.5)

358 (33.4)

316 (31.9)

247 (33.6)

142 (32.8)

473.5 (33.8)

269 (42.0)

 Stage III

233.5 (9.2)

211 (7.9)

97 (9.0)

82 (8.3)

72 (9.8)

35 (8.1)

122 (8.7)

64 (10.0)

 Stage IV

128 (5.0)

134 (5.0)

52 (4.9)

49 (5.0)

31 (4.2)

24 (5.5)

66.5 (4.8)

54 (8.4)

Subtype

            

 HR+/HER2+

210 (8.2)

171 (6.4)

0.01

74.5 (6.9)

64 (6.4)

0.88

48.5 (6.6)

30 (6.9)

0.59

111.5 (8.0)

62 (9.6)

0.12

 HR+/HER2–

1678 (65.9)

1743 (64.8)

717 (66.7)

657 (66.0)

510 (69.2)

286 (65.6)

921.5 (65.7)

428 (66.3)

 HR−/HER2+

83 (3.3)

65 (2.4)

41.5 (3.9)

33 (3.3)

30 (4.1)

11 (2.5)

42 (3.0)

30 (4.6)

 HR−/HER2−

249 (9.8)

275 (10.2)

112 (10.4)

98 (9.9)

64.5 (8.8)

35 (8.0)

137.5 (9.8)

76 (11.8)

 Unknown

327.5 (12.9)

438 (16.3)

129.5 (12.1)

143 (14.4)

84.5 (11.5)

74 (17.0)

189.5 (13.5)

50 (7.7)

Region

            

 North

257.5 (10.1)

254 (9.4)

0.02

111.5 (10.4)

99 (10.0)

0.74

74 (10.0)

46 (10.6)

0.17

135 (9.6)

71 (11.0)

0.86

 Middle East

230.5 (9.1)

257 (9.6)

98.5 (9.2)

97 (9.8)

71.5 (9.7)

55 (12.6)

123.5 (8.8)

59 (9.1)

 Middle

488 (19.2)

589 (21.9)

214 (19.9)

208 (20.9)

139 (18.9)

94 (21.6)

297.5 (21.2)

132 (20.4)

 West

1010.5 (39.7)

991 (36.8)

406 (37.8)

384 (38.6)

304.5 (41.3)

165 (37.8)

538 (38.4)

246 (38.1)

 South

560.5 (22.0)

600 (22.3)

244.5 (22.8)

207 (20.8)

148.5 (20.1)

76 (17.4)

308 (22.0)

138 (21.4)

Screened

            

 Yes

810 (31.8)

837 (31.1)

0.87

354.5 (33.0)

342 (34.4)

0.43

256.5 (34.8)

172 (39.5)

0.12

455.5 (32.5)

12 (1.9)

0.00

 No

727.5 (28.6)

762 (28.3)

299 (27.8)

275 (27.6)

201.5 (27.3)

107 (24.5)

403.5 (28.8)

282 (43.7)

 Not eligible

961 (37.7)

1023 (38.0)

402.5 (37.5)

345 (34.7)

264.5 (35.9)

140 (32.1)

519.5 (37.1)

328 (50.8)

 Unknown

49 (1.9)

70 (2.6)

18.5 (1.7)

33 (3.3)

15 (2.0)

17 (3.9)

23.5 (1.7)

24 (3.7)

  1. Data are reported as N (%) of patients diagnosed in weeks 2–17 of 2018/2019 or 2020
  2. The p value was calculated on known values only, using the chi-square test to compare patients diagnosed in weeks 2–8, 9–11, 12–13, or 14–17 of 2020 with those diagnosed in the same period from the average for the years 2018 and 2019
  3. DCIS, ductal carcinoma in situ; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; SES, socioeconomic status
  4. aThe average was taken over 2018 and 2019